Program

Day 1

Wednesday, 23^th November 2022

8h30

Registration & welcome coffee

9h15

Welcome Address

9h30

Opening keynote

Harnessing mRNA’s Power: going from one success today to tomorrow full potential

Régis Gervier
Global Head of mRNA Center of Excellence
Sanofi, France

10h00

Coffee Break - Exhibition Hall - B2B Meetings

10h30

Track 1 : Alternative to antibiotics and current antivirals

Session 1

Regulatory hurdles while developing a phage cocktail for Ventilator-Associated Pneumonia in Europe

Sofia Côrte Real
Scientific advisor
TechnoPhage - Portugal

Immune modulation of microbiome:host interactions in acne vulgaris

Sanja Selak
Managing director and CSO
ORIGIMM Biotechnology - Austria

Scalable antibiotic discovery through synthetic biology

Vincent Libis
Research Group Leader
INSERM - France

Track 2 : New advancements in Immunotherapies

Session 1

Antipseudomonal monoclonals

Jean Chastre
PU-PH
APHP - France

Leveraging continuous manufacturing to expand global access to biotherapeutics

Christelle Dagoneau
Senior Vice Presidente, Global Business Development
Just-Evotec Biologics, France

Monoclonal antibodies as immunization: innovation in RSV for all infant protection

Kocfa Chung
Global Medical Expert, Strategy Lead RSV Global Medical Franchise
Sanofi, France

12h00

Lunch - Exhibition Hall - B2B Meetings 2 slots

13h00

Poster Presentation - Exhibition Hall - B2B Meetings 3 slots

14h00

Track 3: Fostering infectious diseases public-private initiatives

Session 1

A new agency: ANRS-MIE, Moving to Emerging Infectious diseases.

Hervé Raoul
Directeur adjoint
ANRS - France

HUB VPH : an international hub devoted to veterinary public health

Régis Villet
Strategic Partnership Manager
Bioaster, France

Track 2 : New advancements in Immunotherapies

Session 2

Anne-Claire Lukaszewicz
Head of Department
Hospices Civils de Lyon - France

Hasan Jafri
Chief Medical Officer
Aridis Pharmaceuticals - USA

14h30

Track 1 : Alternative to antibiotics and current antivirals

Session 2

Dynamic Computational Models of Bacteria: From Target-Identification to Drugs

Ed Siegwart
Director of Microbiology
Oppilotech, United Kingdom

Machine learning for antibiotic discovery against Acinetobacter baumannii

Jon Stokes
Assistant Professor
Stokes Laboratory / McMaster University - Canada

Breakthrough innovation

Session 1

Respiratory Syndrome: Multiplex PCR test for viral straightforward characterization and monitoring of pandemic risks

Laëtitia Villiers
R&D project manager
AXO Science, France

Effective in vivo protection of the broad neutralizing antibody 10-1074 against mucosal cell-associated SHIV infection in non-human primates

Mariangela Cavarelli
Researcher
CEA, France

15h30

Coffe Break - Exhibition Hall - B2B Meetings 3 slots

16h00

Track 1 : Alternative to antibiotics and current antivirals

Session 3

The central role of diagnostics in personalized phage therapy and our rapid automated phagogram

Bob Blasdel
Research Director
Vésale Bioscience – Belgique

Alternative approach to discover small molecule antibiotics

Sébastien Coyne
Project and Team Leader in Bacteriology Omics Platform
Evotec, France

Generation of functional monoclonal antibodies by different platforms for antivirus research and immunotherapy

Yu-Chih Lin
Technical Specialist
Sino Biological, Germany

New psVLP neutralization assay using bioluminescence: Proof of Concept on SARS-CoV-2

Florian Mignot
Cell -based assays specialist
Promega, France

Multi-modal immune profiling at single cell resolution

Koen De Gelas
Science and Technology Advisor
10x Genomics, USA

Breakthrough innovation

Session 2

Multi-omics longitudinal analysis as a new deep characterization tool for bacterial fermentation optimization

Charlotte Mignon
Research Scientist
Bioaster, France

Validation of a model of SARS-CoV-2 transmission in the Syrian golden hamster

Marianne Figl
Study Director
Voxcan, France

Intracellular Staphylococcus aureus replicative dynamics monitoring under antibiotics challenges: highlighting persisters

Florian C. Marro
PhD Student
Evotec ID, France

Microalgae Extracellular Vesicles: an effective delivery system for human therapeutics and vaccines

Manuel Vega
CEO
AGS Therapeutics, France

17h30

End of Day 1

19h30

Cocktail Diner at Musée des Confluences (booking mandatory)

Day 2

Thursday, 24^th November 2022

8h30

Welcome coffee

9h00

Opening

Fabio Bagnoli
Senior Scientific Director
GlaxoSmithKline, Italy

A bird’s eye view of SARS-CoV2 vaccines: from vaccine immunology to vaccine effectiveness

Robbert Van Der Most
Vice President Translational Science
BioNTech, Germany

10h00

Coffe Break - Exhibition Hall - B2B Meetings

10h30

Track 4 : Innovative vaccines

Session 1

Long-lasting effects of vaccination on innate myeloid cells

Anne-Sophie Beignon
Researcher
Inserm, CEA, IMVA-HB/IDMIT - France

A nasal vaccine to end the COVID-19 pandemic?

Isabelle Dimier-Poisson
CSO
LoValTech - France

Patrick Barillot
CEO
LoValTech - France

Transboundary and Emerging Diseases: Getting ready

Jeroen Kortekaas
Scientific Director, Transboundary and Emerging Diseases
Boehringer Ingelheim, France

Immunotherapies for infectious diseases

Pedro Madureira
Co-founder and CSO
Immunethep, Portugal

Ensuring clinical availability of vaccine delivery systems, immunostimulators and combined adjuvant systems beyond COVID-19.

Dennis Christensen
Head of Global Research and Development, Adjuvant Systems
Croda Pharma, Danmark

Track 5 : Diagnostic, prognostic and clinical biomarkers

Session 1

Targeting TREM-1 to Manage Lifethreatening Immune Disorders Caused by Severe Infections - Application in Septic Shock and COVID-19

Margarita Salcedo Magguilli
Chief Development Officer
Inotrem, France

Sepsis-associated immunosuppression: diagnostic issues

Louis Kreitmann
Researcher
bioMérieux, France

Breakthrough innovation

Session 3

Identification of a neutralizing antibody targeting, vaccinia virus, variola virus and the current strain of pandemic monkeypoxvirus

Arnaud Avril
Deputy director of the Microbiology and Infectious Diseases Department
IRBA, Ministère des Armées, France

SEPSI-SCORE : Presentation of a Sepsis risk prediction AI solution

Quentin François
CEO
PREVIA MEDICAL, France

System’s biology acting alternatives to antibiotics and current antivirals obtained by Artificial Intelligence, naturally

Pascal Mayer
CEO
Alphanosos, France

12h30

Lunch - Exhibition Hall - B2B Meetings 2 slots

13h30

Poster Presentation - Exhibition Hall - B2B Meetings 3 slots

14h30

Track 3: Fostering infectious diseases public-private initiatives

Session 2

Fostering infectious diseases public private initiative in the field of antimicrobial resistance

François Lacoste
Executive Vice President, Research & Development
bioMérieux, France
Comité stratégique de filière (CSF) Antibiorésistance - France

Advances of the National Acceleration Strategy for Emerging Infectious Diseases and CBRN threats – France 2030

Nadia Khelef
Coordinator
National Acceleration Strategy Emerging Infectious Diseases and CBRN Threats - France

What pull incentives adapted to SMEs to restore the business model of antibiotics

Florence Séjourné
Founder and Board Member
BEAM Alliance & CEO - Aurobac Therapeutics – France

15h15

Track 4 : Innovative vaccines

Session 2

MOPEVAC, a vaccine plaform against all pathogenic Arenaviruses

Sylvain Baize
PI
Pasteur Institute - France

Protective secretory IgA response by repertoire amplification

Fabio Grassi
Chairman
MV BioTherapeutics, Switzerland

Engineering Bioconjugation Platform for Vaccines Development

Sherif Abouelhadid
Head at Biological and Pharmacological Pillar at Antimicrobial Resistance Centre
London school of Hygiene & Tropical Medicine, United Kingdom

16h30

Best Poster - Annoucemment of next year edition

17h00

End of congress

Program

Day 1

Wednesday, 23th November 2022

Day 2

Thursday, 24th November 2022

ORGANIZERS

Wednesday, 23^th November 2022

Thursday, 24^th November 2022